Quel est le site Web ?

https://www.facebook.com/432202614266447/

IMMUcan

IMMUcan is an (now IHI) project proposing an inclusive immuno-oncology platform.

30/06/2026

Projects have end dates. The knowledge, relationships and experience they create do not. As IMMUcan reaches its conclusion, we are taking a moment to reflect on the lessons learned throughout seven years of collaboration and discovery.

Since 2019, the consortium navigated evolving standards of care, a global pandemic, complex multi-country recruitment, rapidly growing data volumes, and the challenges of integrating clinical, molecular and imaging data at scale.

What did we learn?
🔹 Scientific projects must be able to adapt to changing clinical practices and unexpected events.
🔹 Strong networks matter, as collaboration across hospitals, academia, industry and patient-centred organisations proved critical to overcoming challenges.
🔹 Data quality starts on day one: robust sample tracking, harmonised data collection and early validation save significant time later.
🔹 Infrastructure and analysis planning require dedicated expertise, scalable systems and early involvement of data analysts are key.
🔹 Behind every dataset is a team where trust, communication and long-term collaboration are just as important as technology and processes.

Thank you to everyone who contributed to making IMMUcan more than a research project. It became a truly remarkable scientific journey.
Learn more about the project, its achievements and resources at www.immucan.eu

24/06/2026

One of IMMUcan's most ambitious goals was to create a large-scale molecular profiling resource for cancer research and now that vision has become a reality.

Over more than 7 years, the consortium successfully generated more than 3,000 whole exome sequencing (WES) profiles and 2,600 RNA sequencing profiles from more than 2,500 cancer patients across Europe. This extensive effort required the collaboration of clinicians, researchers, sequencing experts and data scientists working together to unlock new insights into tumour biology and the immune response to cancer.

The resulting dataset represents one of the largest cancer molecular profiling resources generated in Europe to date and will continue to support future discoveries in immuno-oncology long after the project's official end.

Learn more about IMMUcan's research, datasets and scientific outputs: www.immucan.eu

19/06/2026

Over more than seven years of collaboration, discovery and knowledge-sharing have led to a remarkable scientific legacy.

From more than 30 presentations at major international conferences to a growing portfolio of publications, IMMUcan has contributed valuable insights into tumour-immune interactions while supporting the next generation of cancer researchers.

Importantly, the project's impact will continue beyond its official end. Clinical, molecular and imaging datasets generated through IMMUcan will be made available through recognised data repositories, creating a lasting resource for the global cancer research community and enabling future discoveries in immuno-oncology.

A sincere thank you to all patients, researchers, clinicians and partners who made this journey possible.

Learn more about IMMUcan's research, datasets and scientific outputs: www.immucan.eu

12/05/2026

Good morning from Berlin, where the final IMMUcan General Assembly starts today.

Over the past years, IMMUcan has grown into one of the largest efforts of its kind in Europe to profile the tumour microenvironment across cancer types. It feels like the right moment to look at what this project has actually built: patient cohorts across major cancer types, molecular and cellular profiling, spatial transcriptomics, proteomics, plasma profiling, imaging data, and analyses now moving into publications and reusable resources.

The project brought together clinicians, researchers, data scientists, hospitals, academic centres, industry partners, and patient organisations around one shared question: how can we better understand the tumour microenvironment so future cancer treatment becomes more precise?

Over the next two days, we’ll go through the science, the datasets, the publications, the lessons learned, and the work still needed to make sure the results continue to be useful beyond the project.

There’s always something slightly reflective about a final meeting. You start to see the project not just as a series of results, but as something that took time, coordination, and a lot of collective effort to come together.

05/05/2026

Translational insight starts with integrated data.

A recent medRxiv preprint uses IMMUcan’s multi-modal NSCLC dataset to explore how tumour microenvironment features align with histology, molecular alterations, and clinical variables.

This work highlights the value of combining imaging, genomics, and clinical annotation to support clinically meaningful stratification in lung cancer research.

Read the preprint:
https://www.medrxiv.org/content/10.1101/2025.11.10.25339890v1

IMMUcan samples and data are now open for access, supporting discovery that bridges biology and clinical relevance.

👉 Apply for access: https://immucan.eu/how-to-collaborate

15/04/2026

A bioRxiv preprint introduces Cellohood, a new computational framework for identifying cellular neighbourhoods, developed and validated using IMMUcan imaging datasets.

The study shows how large, harmonised spatial datasets enable reproducible, interpretable discovery of tumour microenvironment organisation using advanced computational approaches.

📄 Read the preprint:
https://www.biorxiv.org/content/10.1101/2025.11.10.687184v1

IMMUcan biosamples and data are designed to support exactly this kind of innovative, cross-disciplinary research.

👉 Learn how to collaborate: https://immucan.eu/how-to-collaborate

Adresse

Petit Bruxelles

Site Web

facebook.com

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque IMMUcan publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.